NeoGenomics Reports Revenue of $25.1 Million and Record Adjusted EBITDA of $2.8 Million Driven by a 25% Increase in Test Volume in the Third Quarter of 2015
Go back to NeoGenomics Reports Revenue of $25.1 Million and Record Adjusted EBITDA of $2.8 Million Driven by a 25% Increase in Test Volume in the Third Quarter of 2015| NEOGENOMICS (NASDAQ: NEO) | Delayed: 19.91 +0.02 (0.10%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $19.89 | 52 Week High | $9.54 | |||
| Open | $19.91 | 52 Week Low | $5.49 | |||
| Day High | $20.03 | P/E | 497.75 | |||
| Day Low | $19.40 | EPS | $0.04 | |||
| Volume | 4,400,263 | |||||
